Phase II of POSEIDON: A phase Ib/randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic breast cancer patients …
Cancer Res（2017）
摘要
Primary Objective• To compare investigator-assessed progression free survival (PFS) between Tamoxifen and placebo versus Tamoxifen in combination with Taselisib at the RPTD.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要